ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Amgen and Adaptive pursue COVID-19 antibody therapy

by Ryan Cross
April 10, 2020 | APPEARED IN VOLUME 98, ISSUE 14

 

Amgen and Adaptive Biotechnologies will work together to identify and develop an antibody therapy for COVID-19. Adaptive aims to screen tens of thousands of antibodies produced by B cells in people who have recovered from COVID-19 and find ones that neutralize the virus that causes it, SARS-CoV-2. Amgen will develop and manufacture the best antibodies to test as therapies. Adaptive is also expandinga collaboration with Microsoft to study how T cells respond to the viral infection.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment